Diabetes

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

Diabetes device firm Intarcia taps former ICC Lowe CEO Viviano as marketing lead

By

Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.

New data sets up Jardiance  to displace DPP-4 inhibitors

New data sets up Jardiance to displace DPP-4 inhibitors

By

Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.

Five things for pharma marketers to know: Friday, August 7

Five things for pharma marketers to know: Friday, August 7

By

CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access

By

The Danish drugmaker said it expects an FDA decision about long-acting—and long-delayed—insulin Tresiba in October.

Sanofi launches DTC campaign for Afrezza

Sanofi launches DTC campaign for Afrezza

By

The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.

J&J prepares to defend Remicade market share

J&J prepares to defend Remicade market share

By

Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.

Fit4D expands diabetes program with Healthfirst

The health insurer will offer Fit4D's diabetes coaching program to its members after testing the program during a pilot last year.

Five things for pharma marketers to know: Thursday, June 18

Five things for pharma marketers to know: Thursday, June 18

By

Merck settles a marketing lawsuit for $5.9 million; CVS plans to create diagnostic apps; a survey shows advertising agencies plan to keep head count steady for the rest of the year

Five things for pharma marketers to know: Tuesday, June 16

Five things for pharma marketers to know: Tuesday, June 16

By

Novo Nordisk replaces Sanofi as the top marketer of metabolic drugs; Actavis changed its name to Allergan; access to Medicare Part D has not reduced overall Medicare costs

Sanofi will resubmit lixisenatide to FDA

The drugmaker's once-daily diabetes treatment, lixisenatide, will be sent back to US regulators after Sanofi pulled the submission in 2013 to finish a cardiovascular outcomes trial.

Five things for pharma marketers to know: Tuesday, June 9

Five things for pharma marketers to know: Tuesday, June 9

By

Study shows Merck's Januvia does not increase heart risks; a former Genentech exec launches a behavioral health business; lawmakers want black-box warnings on more opioids

Lilly says peglispro is superior to Sanofi's Lantus

Concerns persist regarding the drug's impact on liver enzymes and fat.

DTC expected to propel Afrezza awareness, not necessarily sales

DTC expected to propel Afrezza awareness, not necessarily sales

By

Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.

Five things for pharma marketers to know, Thursday, June 4

Five things for pharma marketers to know, Thursday, June 4

By

Novartis appeals the ban on its biosimilar Zarxio; AbbVie petitions for distinct biosimilar labels; Sanofi will study Toujeo in a real-world setting

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

By

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Diabetes advocate Manny Hernandez joins digital health firm

Hernandez is known for his ability to bring together patients and pharma. He joined Livongo Health to aid the firm's user experience.

Five things for pharma marketers to know: Thursday, April 30

Five things for pharma marketers to know: Thursday, April 30

By

FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

By

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

By

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

By

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

By

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

By

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

Five things for pharma marketers to know: Friday, April 10

Five things for pharma marketers to know: Friday, April 10

By

AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce

FDA Onglyza panel review set for Tuesday

FDA Onglyza panel review set for Tuesday

By

The panel will focus on heart failure hospitalization rates associated with the diabetes medication.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

By

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

By

Oncology and diabetes medications are expected to be major areas of growth.


Email Newsletters


Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.